What can a 157-year-old phar­ma gi­ant bring to the ta­ble of cell and gene ther­a­pies? Quite a bit, Bay­er says

By now, Bay­er has sketched out in bold strokes some grand plans for cell and gene ther­a­py, ce­ment­ed by big-dol­lar ac­qui­si­tions of plat­form com­pa­nies.

But just how do you stitch to­geth­er a new unit burst­ing with the newest ideas with­in a sto­ried phar­ma?

Ste­fan Oel­rich, the head of Bay­er’s phar­ma di­vi­sion, briefly lift­ed the cur­tain and spot­light­ed three key fac­tors as he took the stage on a vir­tu­al me­dia day, flanked by Emile Nuwaysir and Sheila Mikhail, the chiefs of Blue­Rock and AskBio, who each in­tro­duced their work in a way you’d ex­pect from a biotech CEO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER